


## Caspofungin

<b>Cat. No.:</b>	HY-17006A
<b>CAS No.:</b>	162808-62-0
<b>Molecular Formula:</b>	C <sub>52</sub> H <sub>88</sub> N <sub>10</sub> O <sub>15</sub>
<b>Molecular Weight:</b>	1093.31
<b>Target:</b>	Antibiotic; Fungal; Bacterial
<b>Pathway:</b>	Anti-infection
<b>Storage:</b>	Please store the product under the recommended conditions in the Certificate of Analysis.



### BIOLOGICAL ACTIVITY

<b>Description</b>	Caspofungin is a potent antifungal agent. Caspofungin inhibits the synthesis of the fungal cell wall component $\beta$ -(1,3)-D-glucan <sup>[1][2]</sup> .																
<b>In Vivo</b>	<p>Caspofungin (1-8 mg/kg; i.p.; daily, for 7 days) is able to penetrate the CNS in mice and achieve concentrations that result in the reduction of Candida burden in the brain<sup>[1]</sup>.</p> <p>Caspofungin (0.41-41 <math>\mu</math>M; i.p.; for 5 weeks; male C57BL/6 mice) is a safe antifungal agent at vitreal concentrations of 0.41 to 4.1 <math>\mu</math>M in mice<sup>[2]</sup>.</p> <p>MCE has not independently confirmed the accuracy of these methods. They are for reference only.</p> <table border="1"> <tr> <td>Animal Model:</td> <td>Complement component 5-deficient DBA/2N mice<sup>[1]</sup></td> </tr> <tr> <td>Dosage:</td> <td>1, 2, 4 and 8 mg/kg</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; daily, for 7 days.</td> </tr> <tr> <td>Result:</td> <td>Reduced the concentration of Candida load in the brain.</td> </tr> </table> <table border="1"> <tr> <td>Animal Model:</td> <td>Male C57BL/6 mice<sup>[2]</sup></td> </tr> <tr> <td>Dosage:</td> <td>0.41, 1.2, 2.5, 4.1, and 41 <math>\mu</math>M</td> </tr> <tr> <td>Administration:</td> <td>Intraperitoneal injection; for 5 weeks</td> </tr> <tr> <td>Result:</td> <td>Had nonsignificant alterations in their ERG waveforms from 0.41 to 4.1 <math>\mu</math>M.</td> </tr> </table>	Animal Model:	Complement component 5-deficient DBA/2N mice <sup>[1]</sup>	Dosage:	1, 2, 4 and 8 mg/kg	Administration:	Intraperitoneal injection; daily, for 7 days.	Result:	Reduced the concentration of Candida load in the brain.	Animal Model:	Male C57BL/6 mice <sup>[2]</sup>	Dosage:	0.41, 1.2, 2.5, 4.1, and 41 $\mu$ M	Administration:	Intraperitoneal injection; for 5 weeks	Result:	Had nonsignificant alterations in their ERG waveforms from 0.41 to 4.1 $\mu$ M.
Animal Model:	Complement component 5-deficient DBA/2N mice <sup>[1]</sup>																
Dosage:	1, 2, 4 and 8 mg/kg																
Administration:	Intraperitoneal injection; daily, for 7 days.																
Result:	Reduced the concentration of Candida load in the brain.																
Animal Model:	Male C57BL/6 mice <sup>[2]</sup>																
Dosage:	0.41, 1.2, 2.5, 4.1, and 41 $\mu$ M																
Administration:	Intraperitoneal injection; for 5 weeks																
Result:	Had nonsignificant alterations in their ERG waveforms from 0.41 to 4.1 $\mu$ M.																

### CUSTOMER VALIDATION

- EMBO Rep. 2022 Apr 11;e53932.
- Cell Physiol Biochem. 2016 Aug 12;39(3):939-949.

See more customer validations on [www.MedChemExpress.com](http://www.MedChemExpress.com)

---

## REFERENCES

- [1]. Flattery AM, et, al. Efficacy of caspofungin in a juvenile mouse model of central nervous system candidiasis. *Antimicrob Agents Chemother.* 2011 Jul;55(7):3491-7.
- [2]. Mojumder DK, et, al. Evaluating retinal toxicity of intravitreal caspofungin in the mouse eye. *Invest Ophthalmol Vis Sci.* 2010 Nov;51(11):5796-803.
- 

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA